# Targeting the retinoic acid signaling pathway for mitigating visual impairmen in retinal degenerative disorders > **NIH NIH R01** · UNIVERSITY OF CALIFORNIA BERKELEY · 2024 · $484,829 ## Abstract ABSTRACT Light responses are initiated in rod and cone photoreceptors, processed by retinal interneurons, and synaptically transmitted to retinal ganglion cells (RGCs), which send information, in the form of spike trains, to the brain. In degenerative retinal disorders, including Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP), the photoreceptors gradually die off, depriving downstream neurons of light-sensitive input. However, recent evidence suggests that losing photoreceptors is only part of the problem in these disorders. Downstream retinal neurons become hyperactive, with retinal ganglion cells (RGCs) firing spontaneously in darkness at up to 10 times faster than in healthy retina, corrupting the proper encoding of visual information. We recently reported that retinoic acid (RA), a small molecule that activates gene transcription, is the signal that triggers RGC hyperactivity. Blocking the receptor for RA in vivo can reverse hyperactivity, unmasking light responses that would otherwise be obscured by spontaneous RGC firing. Blocking RA receptors in the retina also augments the contrast-sensitivity of learned visual behaviors in a mouse model of RP. Our goal in this project is to assess whether drugs or gene therapies that inhibit RA signaling can improve vision in mouse models of RP, with the hope of extending useful vision for years in humans with degenerative retinal disorders. First, we will ask whether inhibiting RA signaling not only improves light-sensitivity, but actually improves conscious visual function in vision-impaired mice, assessed with behavioral tests of contrast sensitivity and spatial frequency threshold. We will determine how when during the degeneration process RA inhibitors are most effective, revealing the optimal time for beginning treatment. Second, we will investigate retinal neurons that lie upstream of RGCs, namely bipolar cells and amacrine cells. We will ask whether pathophysiological changes in these presynaptic neurons are also induced by elevated RA signaling and whether inhibiting RAR can reverse these changes, providing critical information for effective cellular targeting of gene therapy. Third, we will test whether vision can be improved by inhibiting the enzyme that synthesizes RA, with a re-purposed drug that is already FDA-approved for other indications, paving the way for human clinical studies. Taken together, this project will establish the proof-of-principle behind a new treatment paradigm for augmenting vision in retinal degenerative disorders. ## Key facts - **NIH application ID:** 10899489 - **Project number:** 5R01EY024334-09 - **Recipient organization:** UNIVERSITY OF CALIFORNIA BERKELEY - **Principal Investigator:** RICHARD H KRAMER - **Activity code:** R01 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2024 - **Award amount:** $484,829 - **Award type:** 5 - **Project period:** 2015-09-01 → 2025-07-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10899489 ## Citation > US National Institutes of Health, RePORTER application 10899489, Targeting the retinoic acid signaling pathway for mitigating visual impairmen in retinal degenerative disorders (5R01EY024334-09). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10899489. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*